Keep an eye on CRISPR Therapeutics (CRSP), we said on November 1.
“The gene editing stock is starting to take off after a favorable US FDA panel review of the drug exa-cel for sickle-cell disease. Now, should the US FDA approve it on the panel’s vote, we could be looking at the first approved drug using the gene-editing technology,” we noted.
At the time, CRSP traded at around $40. Today, it’s up to $71 and could see higher highs, with big catalysts ahead. For one, we’re nearing potential US FDA approval on December 8.
A week later, we highlighted opportunity in Generac Holdings (GNRC), and watched the stock pop from about $109.62 to $122.77. We still like the stock heading into colder months. Then, we highlighted Editas (EDIT), which should piggyback CRSP, at $10.12. It’s now up to $11.09.
And just last week, we highlighted General Motors (GM) at $28.89 thanks to its buyback and dividend announcements. That stock is now up to $33 and running.
We’d love to hear how you’re doing with these trade ideas if you have a chance.
Ian Cooper is an experienced trader who uses a combination of technical, fundamental, and news analysis to help individual investors grow their wealth. Ian’s Premium Options Strategies